Tripartite motif‑containing 11 regulates the proliferation and apoptosis of breast cancer cells

Dai,Xianping; Geng,Feng; Li,Mengshun; Liu,Ming

doi:10.3892/or.2019.7015

Tripartite motif‑containing 11 regulates the proliferation and apoptosis of breast cancer cells

Authors:
- Xianping Dai
- Feng Geng
- Mengshun Li
- Ming Liu
View Affiliations

Affiliations: School of Pharmacy, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: February 14, 2019 https://doi.org/10.3892/or.2019.7015
Pages: 2567-2574

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer, an increasing health problem worldwide, is the second major cause of cancer‑associated mortality in females. Studies have focused on the pathogenesis of breast cancer for decades, but the underlying mechanisms have not been fully elucidated. Tripartite motif‑containing 11 (TRIM11), a novel oncogene that was recently identified, was reported to function in various types of cancer, including ovarian and lung cancer. In the present study, high expression levels of TRIM11 were detected in breast cancer tissues by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, which suggested that TRIM11 was likely to function in the progression of breast cancer. Downregulation of TRIM11 in MCF‑7 and MDA‑MB‑231 cells inhibited cell proliferation and promoted cell apoptosis, accompanied by increased phosphatase and tensin homolog deleted on chromosome 10 (PTEN), p53 and Bcl‑2‑associated X protein, and decreased B‑cell lymphoma 2, phosphorylated c‑Jun N‑terminal kinase 1/2 (p‑JNK1/2) and phosphorylated extracellular signal‑regulated kinases 1/2 (p‑ERK1/2), whereas the overexpression of TRIM11 completely reversed these effects. Furthermore, TRIM11 downregulation enhanced the pro‑apoptotic effect of chemotherapy drugs on breast cancer cells, and high levels of TRIM11 expression were observed in cisplatin‑ and paclitaxel‑resistant breast cancer tissues. These data indicated that TRIM11 is crucial to the development of breast cancer, and TRIM11 downregulation may benefit the treatment of breast cancer by regulating ERK1/2 and JNK1/2 signaling and the expression of apoptosis‑associated genes.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al: SEER cancer statistics review, 1975–2012, National Cancer Institute. 2013.
2	Demicheli R, Valagussa P and Bonadonna G: Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer. 85:490–492. 2001. View Article : Google Scholar : PubMed/NCBI
3	Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F and Taeger K: Tumor cells in blood shed from the surgical field. Arch Surg. 130:387–393. 1995. View Article : Google Scholar : PubMed/NCBI
4	Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
5	Wang J and Wu GS: Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
6	Walsh V and Goodman J: From taxol to Taxol: The changing identities and ownership of an anti-cancer drug. Med Anthropol. 21:307–336. 2002. View Article : Google Scholar : PubMed/NCBI
7	Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. 68:1104–1109. 1993. View Article : Google Scholar : PubMed/NCBI
8	Manfredi JJ and Horwitz SB: Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther. 25:83–125. 1984. View Article : Google Scholar : PubMed/NCBI
9	Kampan NC, Madondo MT, Mcnally OM, Quinn M and Plebanski M: Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015:4130762015. View Article : Google Scholar : PubMed/NCBI
10	Pritchard JE, Dillon PM, Conaway MR, Silva CM and Parsons SJ: A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model. Oncology. 83:305–320. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R and Dash S: Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 178:838–852. 2011. View Article : Google Scholar : PubMed/NCBI
12	Siena L, Pace E, Ferraro M, Di Sano C, Melis M, Profita M, Spatafora M and Gjomarkaj M: Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing. Immunology. 141:242–255. 2014. View Article : Google Scholar : PubMed/NCBI
13	García MA, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, et al: The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One. 6:e238872011. View Article : Google Scholar : PubMed/NCBI
14	Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, et al: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
15	Tomar D and Singh R: TRIM family proteins: Emerging class of RING E3 ligases as regulator of NF-κB pathway. Biol Cell. 107:22–40. 2015. View Article : Google Scholar : PubMed/NCBI
16	Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer. 11:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Shi W, Shi H, Lu S, Kang W, Chao S, He J, Jin W, Lv X, Zou H and Shu Y: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. J Exp Clin Cancer Res. 35:1002016. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Zhong J, Li SW, Li JZ, Zhou M, Chen Y, Sang Y and Liu L: TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer. Oncotarget. 7:86755–86765. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Sun J and Ma J: Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11. Oncol Lett. 14:2125–2130. 2017. View Article : Google Scholar : PubMed/NCBI
20	Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, Gleizes M, Thénot S, Bibeau F, Theillet C and Cavaillès V: Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol. 178:1461–1469. 2011. View Article : Google Scholar : PubMed/NCBI
21	Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, et al: TRIM24 links a non-canonical histone signature to breast cancer. Nature. 468:927–932. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ai L, Kim WJ, Alpay M, Ming T, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al: TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Hong JY, Kang B, Kim A, Hwang S, Ahn J, Lee S, Kim J, Park JH and Cheon DS: Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J. 8:3302011. View Article : Google Scholar : PubMed/NCBI
25	Gao G and Dou QP: G₁ phase-dependent expression of Βcl-2 mRNA and protein correlates with chemoresistance of human cancer cells. Mol Pharmacol. 58:1001–1010. 2000. View Article : Google Scholar : PubMed/NCBI
26	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
27	Bu Y, Lu C, Bian C, Wang J, Li J, Zhang B, Li Z, Brewer G and Zhao RC: Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncol Rep. 21:13–17. 2009.PubMed/NCBI
28	Bhatnagar S, Gazin C, Chamberlain L, Ou J, Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N and Green MR: TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. Nature. 516:116–120. 2014.PubMed/NCBI
29	Li Z, Li X, Wei D, Sun C, Guo D and Zhang L: Mmu-miR-1894-3p inhibits cell proliferation and migration of breast cancer cells by targeting Trim46. Int J Mol Sci. 17:E6092016. View Article : Google Scholar : PubMed/NCBI
30	Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
31	Miyashita T, Harigai M, Hanada M and Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:3131–3135. 1994.PubMed/NCBI
32	Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 86:499–504. 1994. View Article : Google Scholar : PubMed/NCBI
33	Zhao G, Zhu Y, Eno CO, Liu Y, Deleeuw L, Burlison JA, Chaires JB, Trent JO and Li C: Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol. 34:1198–1207. 2014. View Article : Google Scholar : PubMed/NCBI
34	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
35	Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
36	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
37	Lin A: Activation of the JNK signaling pathway: Breaking the brake on apoptosis. Bioessays. 25:17–24. 2003. View Article : Google Scholar : PubMed/NCBI
38	Nunes-Xavier CE, Elson A and Pulido R: Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells. J Biol Chem. 287:3433–3444. 2012. View Article : Google Scholar : PubMed/NCBI
39	Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM and Davis RJ: Role of JNK in mammary gland development and breast cancer. Cancer Res. 72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI